Trials / Completed
CompletedNCT00406601
BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas
Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-based Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Istituto Clinico Humanitas · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study (\*) is to evaluate the progression free survival rate at 6 months, response rate, overall disease control rate, overall survival of BAY-43-9006 in soft tissue sarcoma patients. (\*) as per Protocol Amendment No. 1 of 16 April 2007 approved by local IEC on 24 July 2007
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (BAY-43-9006) | 800 mg/die orally on a continuous basis |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2010-06-01
- Completion
- 2010-09-01
- First posted
- 2006-12-04
- Last updated
- 2010-09-02
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00406601. Inclusion in this directory is not an endorsement.